Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenza virus therapies

Jiayu Liao; George Way; Vipul Madahar

doi:10.1016/j.medidd.2020.100037

Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenza virus therapies

Med Drug Discov. 2020 Mar:5:100037. doi: 10.1016/j.medidd.2020.100037. Epub 2020 Apr 13.

Authors

Jiayu Liao¹, George Way¹, Vipul Madahar¹

Affiliation

¹ Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.

Abstract

The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.

Keywords: COVID-19; Host factor; Influenza virus; SARS-CoV-2; Therapeutics; drug discovery.

Publication types

Editorial